Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Apr;25(4):570-581.
doi: 10.1007/s12012-025-09980-8. Epub 2025 Mar 6.

Apatinib-Induced Hypertension Correlates with Improved Prognosis in Solid Tumor Patients

Caie Li  1 , Jie Ma  1 , Qiongying Wang  1 , Liping Ma  2 , Juncheng Han  1   3 , Yali Qi  4 , Xiaxia Pei  4 , Jing Yu  5
Affiliations
Multicenter Study

Apatinib-Induced Hypertension Correlates with Improved Prognosis in Solid Tumor Patients

Caie Li et al. Cardiovasc Toxicol. 2025 Apr.

Abstract

This study evaluated the occurrence of apatinib-induced hypertension and its impact on the prognosis of patients with solid tumors. A retrospective cohort study with prospective follow-up was conducted on 769 patients treated with apatinib from 2014 to 2021 across three hospitals. Patients were categorized into hypertension and non-hypertension groups. The primary outcome was overall survival (OS), with progression-free survival (PFS) as a secondary outcome. Apatinib-induced hypertension occurred in 33.3% of patients and was associated with significantly longer OS (HR 0.40, 95% CI [0.37-0.48], p < 0.0001) and PFS (HR 0.41, 95% CI [0.35-0.49], p < 0.001). Subgroup analysis confirmed these findings in all cancer types, except for PFS in non-small cell lung cancer. Hypertension may serve as a predictive biomarker for improved anti-tumor efficacy.

Keywords: Apatinib; Cardio-oncology; Cardiotoxicity; Hypertension; VEGF inhibitors.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interests: The authors declare no competing interests. Ethical Approval: The study received approval from the institutional ethics committee. Consent to Participate: This study was conducted in accordance with the Declaration of Helsinki and was approved by the appropriate institutional review board or ethics committee. Informed consent was obtained from all individual participants included in the study. Participants were provided with detailed information regarding the purpose, procedures, potential risks, and benefits of the study. They were assured that their participation was voluntary and that they could withdraw from the study at any time without any consequences. Consent for Publication: All authors consent to the publication of this manuscript in Cardiovascular Drugs and Therapy.

References

    1. Bæk Møller, N., Budolfsen, C., Grimm, D., Krüger, M., Infanger, M., Wehland, M., & Magnusson, E. N. (2019). Drug-induced hypertension caused by multikinase inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in renal cell carcinoma treatment. International Journal of Molecular Sciences, 20(19), 4712. https://doi.org/10.3390/ijms20194712 - DOI - PubMed - PMC
    1. Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., & Cutter, D. J. (2022). 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS). European Heart Journal-Cardiovascular Imaging, 23(10), e333-465. - DOI - PubMed
    1. Dobbin, S. J. H., Cameron, A. C., Petrie, M. C., Jones, R. J., Touyz, R. M., & Lang, N. N. (2018). Toxicity of cancer therapy: What the cardiologist needs to know about angiogenesis inhibitors. Heart (British Cardiac Society), 104(24), 1995–2002. https://doi.org/10.1136/heartjnl-2018-313726 - DOI - PubMed
    1. Herrmann, J., Lenihan, D., Armenian, S., Barac, A., Blaes, A., Cardinale, D., Carver, J., Dent, S., Ky, B., Lyon, A. R., López-Fernández, T., Fradley, M. G., Ganatra, S., Curigliano, G., Mitchell, J. D., Minotti, G., Lang, N. N., Liu, J. E., Neilan, T. G., … Valent, P. (2022). Defining cardiovascular toxicities of cancer therapies: an international cardio-oncology society (IC-OS) consensus statement. European Heart Journal, 43(4), 280–299. - DOI - PubMed
    1. Kidoguchi, S., Sugano, N., Tokudome, G., Yokoo, T., Yano, Y., Hatake, K., & Nishiyama, A. (2021). New concept of onco-hypertension and future perspectives. Hypertension, 77(1), 16–27. https://doi.org/10.1161/HYPERTENSIONAHA.120.16044 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources